Byhealth (300146) Q3 2025 earnings summary

Executive summary

• Operating income for Jan–Sept 2025 was RMB 4.92 billion, down 14.27% year-over-year; net profit attributable to shareholders rose 4.45% to RMB 907 million for the same period.

• Third quarter single-quarter revenue and net profit both achieved year-over-year growth despite a challenging consumption environment and fierce competition.

• Strategic focus included innovation in core product categories, omni-channel quality and efficiency, and digitalization.

Financial highlights

• Q3 operating income: RMB 1.38 billion, up 23.45% compared to the previous quarter.

• Q3 net profit attributable to shareholders: RMB 171 million, up 861.91% sequentially.

• Basic and diluted EPS for Jan–Sept 2025: RMB 0.53, up 3.92% year-over-year.

• Net cash flow from operating activities for Jan–Sept 2025: RMB 921 million, up 170.13% year-over-year.

• Total assets at period end: RMB 14.00 billion; owner's equity: RMB 11.31 billion.

Outlook and guidance

• Continued focus on operating quality improvement, product innovation, and digital transformation to drive future growth.